Associations - HER2 inhibitor

HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pyrotinib + inetetamab Sensitive: C3 – Early Trials ESMO Asia 2023 - 6 days (New C3) pyrotinib + inetetamab Sensitive : C3 ESMO Asia 2023 - 6d	pyrotinib + inetetamab Sensitive: C3 – Early Trials ESMO Asia 2023 - 6 days pyrotinib + inetetamab Sensitive : C3 ESMO Asia 2023 - 6 days - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	camrelizumab + pyrotinib Sensitive: C3 – Early Trials EClinicalMedicine - 1 week (New C3) camrelizumab + pyrotinib Sensitive : C3 EClinicalMedicine - 1wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials EClinicalMedicine - 1 week camrelizumab + pyrotinib Sensitive : C3 EClinicalMedicine - 1 week - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	camrelizumab + pyrotinib Sensitive: C3 – Early Trials EClinicalMedicine - 1 week (New C3) camrelizumab + pyrotinib Sensitive : C3 EClinicalMedicine - 1wk	camrelizumab + pyrotinib Sensitive: C3 – Early Trials EClinicalMedicine - 1 week camrelizumab + pyrotinib Sensitive : C3 EClinicalMedicine - 1 week - (New C3)
EGFR L833V + EGFR H835L	Non Small Cell Lung Cancer	EGFR L833V + EGFR H835L	Non Small Cell Lung Cancer	afatinib + anlotinib Sensitive: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week (New C4) afatinib + anlotinib Sensitive : C4 Zhongguo Fei Ai Za Zhi - 1wk	afatinib + anlotinib Sensitive: C4 – Case Studies Zhongguo Fei Ai Za Zhi - 1 week afatinib + anlotinib Sensitive : C4 Zhongguo Fei Ai Za Zhi - 1 week - (New C4)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pyrotinib Sensitive: C3 – Early Trials Clin Colorectal Cancer - 2 weeks (New C3) trastuzumab + pyrotinib Sensitive : C3 Clin Colorectal Cancer - 2wk	trastuzumab + pyrotinib Sensitive: C3 – Early Trials Clin Colorectal Cancer - 2 weeks trastuzumab + pyrotinib Sensitive : C3 Clin Colorectal Cancer - 2 weeks - (New C3)
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	HER2 inhibitor Sensitive: C3 – Early Trials Hum Pathol - 2 weeks (New C3) HER2 inhibitor Sensitive : C3 Hum Pathol - 2wk	HER2 inhibitor Sensitive: C3 – Early Trials Hum Pathol - 2 weeks HER2 inhibitor Sensitive : C3 Hum Pathol - 2 weeks - (New C3)
ER negative	HER2 Positive Breast Cancer	ER negative	HER2 Positive Breast Cancer	HER2 inhibitor Sensitive: C3 – Early Trials Hum Pathol - 2 weeks (New C3) HER2 inhibitor Sensitive : C3 Hum Pathol - 2wk	HER2 inhibitor Sensitive: C3 – Early Trials Hum Pathol - 2 weeks HER2 inhibitor Sensitive : C3 Hum Pathol - 2 weeks - (New C3)
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	pyrotinib Sensitive: C3 – Early Trials Clin Colorectal Cancer - 2 weeks (New C3) pyrotinib Sensitive : C3 Clin Colorectal Cancer - 2wk	pyrotinib Sensitive: C3 – Early Trials Clin Colorectal Cancer - 2 weeks pyrotinib Sensitive : C3 Clin Colorectal Cancer - 2 weeks - (New C3)
HER-2 positive + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	HER-2 positive + PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	pembrolizumab + trastuzumab Sensitive: A1 - Approval FDA - 3 weeks (New A1) pembrolizumab + trastuzumab Sensitive : A1 FDA - 3wk	pembrolizumab + trastuzumab Sensitive: A1 - Approval FDA - 3 weeks pembrolizumab + trastuzumab Sensitive : A1 FDA - 3 weeks - (New A1)
HER-2 positive + PD-L1 expression	Gastric Cancer	HER-2 positive + PD-L1 expression	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval FDA - 3 weeks (New A1) pembrolizumab + trastuzumab Sensitive : A1 FDA - 3wk	pembrolizumab + trastuzumab Sensitive: A1 - Approval FDA - 3 weeks pembrolizumab + trastuzumab Sensitive : A1 FDA - 3 weeks - (New A1)
HER-2 positive + TP53 mutation	Biliary Tract Cancer	HER-2 positive + TP53 mutation	Biliary Tract Cancer	trastuzumab Resistant: C3 – Early Trials J Clin Oncol - 3 weeks (New C3) trastuzumab Resistant : C3 J Clin Oncol - 3wk	trastuzumab Resistant: C3 – Early Trials J Clin Oncol - 3 weeks trastuzumab Resistant : C3 J Clin Oncol - 3 weeks - (New C3)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	HER2 inhibitor + Erythropoiesis stimulating agent Sensitive: C3 – Early Trials Breast Cancer Res Treat - 3 weeks (New C3) HER2 inhibitor + Erythropoiesis stimulating agent Sensitive : C3 Breast Cancer Res Treat - 3wk	HER2 inhibitor + Erythropoiesis stimulating agent Sensitive: C3 – Early Trials Breast Cancer Res Treat - 3 weeks HER2 inhibitor + Erythropoiesis stimulating agent Sensitive : C3 Breast Cancer Res Treat - 3 weeks - (New C3)
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	bevacizumab + mobocertinib Sensitive: C4 – Case Studies JTO Clin Res Rep - 3 weeks (New C4) bevacizumab + mobocertinib Sensitive : C4 JTO Clin Res Rep - 3wk	bevacizumab + mobocertinib Sensitive: C4 – Case Studies JTO Clin Res Rep - 3 weeks bevacizumab + mobocertinib Sensitive : C4 JTO Clin Res Rep - 3 weeks - (New C4)
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pyrotinib Sensitive: B - Late Trials BMJ - 4 weeks (New B) trastuzumab + pyrotinib Sensitive : B BMJ - 4wk	trastuzumab + pyrotinib Sensitive: B - Late Trials BMJ - 4 weeks trastuzumab + pyrotinib Sensitive : B BMJ - 4 weeks - (New B)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials SITC 2023 - 4 weeks (New C3) Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3 SITC 2023 - 4wk	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials SITC 2023 - 4 weeks Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3 SITC 2023 - 4 weeks - (New C3)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	trastuzumab + abemaciclib Sensitive: C3 – Early Trials Clin Cancer Res - 4 weeks (New C3) trastuzumab + abemaciclib Sensitive : C3 Clin Cancer Res - 4wk	trastuzumab + abemaciclib Sensitive: C3 – Early Trials Clin Cancer Res - 4 weeks trastuzumab + abemaciclib Sensitive : C3 Clin Cancer Res - 4 weeks - (New C3)
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials SITC 2023 - 4 weeks (New C3) Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3 SITC 2023 - 4wk	Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive: C3 – Early Trials SITC 2023 - 4 weeks Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T Sensitive : C3 SITC 2023 - 4 weeks - (New C3)
High PLR	HER2 Positive Breast Cancer	High PLR	HER2 Positive Breast Cancer	pyrotinib Resistant: C3 – Early Trials Transl Cancer Res - 4 weeks (New C3) pyrotinib Resistant : C3 Transl Cancer Res - 4wk	pyrotinib Resistant: C3 – Early Trials Transl Cancer Res - 4 weeks pyrotinib Resistant : C3 Transl Cancer Res - 4 weeks - (New C3)
High MLR	HER2 Positive Breast Cancer	High MLR	HER2 Positive Breast Cancer	pyrotinib Resistant: C3 – Early Trials Transl Cancer Res - 4 weeks (New C3) pyrotinib Resistant : C3 Transl Cancer Res - 4wk	pyrotinib Resistant: C3 – Early Trials Transl Cancer Res - 4 weeks pyrotinib Resistant : C3 Transl Cancer Res - 4 weeks - (New C3)
High NLR	HER2 Positive Breast Cancer	High NLR	HER2 Positive Breast Cancer	pyrotinib Resistant: C3 – Early Trials Transl Cancer Res - 4 weeks (New C3) pyrotinib Resistant : C3 Transl Cancer Res - 4wk	pyrotinib Resistant: C3 – Early Trials Transl Cancer Res - 4 weeks pyrotinib Resistant : C3 Transl Cancer Res - 4 weeks - (New C3)
Low PLR	HER2 Positive Breast Cancer	Low PLR	HER2 Positive Breast Cancer	pyrotinib Sensitive: C3 – Early Trials Transl Cancer Res - 4 weeks (New C3) pyrotinib Sensitive : C3 Transl Cancer Res - 4wk	pyrotinib Sensitive: C3 – Early Trials Transl Cancer Res - 4 weeks pyrotinib Sensitive : C3 Transl Cancer Res - 4 weeks - (New C3)
HER-2 expression	Gastric Cancer	HER-2 expression	Gastric Cancer	ado-trastuzumab emtansine + AST-301 Sensitive: D – Preclinical SITC 2023 - 4 weeks (New D) ado-trastuzumab emtansine + AST-301 Sensitive : D SITC 2023 - 4wk	ado-trastuzumab emtansine + AST-301 Sensitive: D – Preclinical SITC 2023 - 4 weeks ado-trastuzumab emtansine + AST-301 Sensitive : D SITC 2023 - 4 weeks - (New D)
EGFR exon 19 deletion	Non Small Cell Lung Cancer	EGFR exon 19 deletion	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR L858R	Non Small Cell Lung Cancer	EGFR L858R	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1	trastuzumab + pertuzumab Sensitive: A1 - Approval trastuzumab + pertuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1	margetuximab Sensitive: A1 - Approval margetuximab Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1	afatinib Sensitive: A1 - Approval afatinib Sensitive : A1
EGFR exon 20 insertion	Non Small Cell Lung Cancer	EGFR exon 20 insertion	Non Small Cell Lung Cancer	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1	mobocertinib Sensitive: A1 - Approval mobocertinib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1	pembrolizumab + trastuzumab Sensitive: A1 - Approval pembrolizumab + trastuzumab Sensitive : A1
HR positive	HER2 Positive Breast Cancer	HR positive	HER2 Positive Breast Cancer	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1	neratinib Sensitive: A1 - Approval neratinib Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1	trastuzumab Sensitive: A1 - Approval trastuzumab Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1	pertuzumab/trastuzumab/hyaluronidase-zzxf Sensitive: A1 - Approval pertuzumab / trastuzumab / hyaluronidase-zzxf Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1	trastuzumab-qyyp Sensitive: A1 - Approval trastuzumab-qyyp Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1	trastuzumab-dttb Sensitive: A1 - Approval trastuzumab-dttb Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Hormone Receptor Positive Breast Cancer	HER-2 overexpression	Hormone Receptor Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	HER2 Positive Breast Cancer	HER-2 amplification	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	HER2 Positive Breast Cancer	HER-2 overexpression	HER2 Positive Breast Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 positive	Gastroesophageal Junction Adenocarcinoma	HER-2 positive	Gastroesophageal Junction Adenocarcinoma	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 overexpression	Gastric Cancer	HER-2 overexpression	Gastric Cancer	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1	trastuzumab-dkst Sensitive: A1 - Approval trastuzumab-dkst Sensitive : A1
HER-2 amplification	Hormone Receptor Positive Breast Cancer	HER-2 amplification	Hormone Receptor Positive Breast Cancer	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1	trastuzumab-anns Sensitive: A1 - Approval trastuzumab-anns Sensitive : A1

HER2 inhibitor

HER2 inhibitor

Associations(1162)

Associations
(1162)